NASDAQ:CALA Calithera Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.46 -0.09 (-3.53%) (As of 06/30/2022 05:48 PM ET) Add Compare Share Today's Range$2.39▼$2.5950-Day Range$2.41▼$55.0052-Week Range$2.31▼$49.80Volume47,500 shsAverage Volume141,348 shsMarket Capitalization$11.96 millionP/E RatioN/ADividend YieldN/APrice Target$50.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CALA Stock Forecast (MarketRank)Overall MarketRank™1.85 out of 5 starsMedical Sector745th out of 1,433 stocksPharmaceutical Preparations Industry361st out of 684 stocksAnalyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingCalithera Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.00, Calithera Biosciences has a forecasted upside of 1,932.5% from its current price of $2.46.Amount of Analyst CoverageCalithera Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesCalithera Biosciences has received 339 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCalithera Biosciences has received 157 “underperform” votes. (Add your “underperform” vote.)Community SentimentCalithera Biosciences has received 68.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote “Outperform” if you believe CALA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCalithera Biosciences does not currently pay a dividend.Dividend GrowthCalithera Biosciences does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calithera Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Calithera Biosciences is held by insiders.Percentage Held by Institutions55.84% of the stock of Calithera Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Calithera Biosciences are expected to grow in the coming year, from ($11.70) to ($7.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Calithera Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calithera Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalithera Biosciences has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Calithera Biosciences (NASDAQ:CALA)Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Read More CALA Stock News HeadlinesJune 29, 2022 | americanbankingnews.comCalithera Biosciences, Inc. (NASDAQ:CALA) Short Interest Down 93.7% in JuneJune 23, 2022 | benzinga.comCalithera Commences Mid-Stage Study Of DLBCL CandidateJune 23, 2022 | finance.yahoo.comCalithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell LymphomaJune 15, 2022 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces 1-for-20 Reverse Stock SplitJune 14, 2022 | seekingalpha.comCalithera Biosciences announces 1-for-20 reverse stock split to regain listing complianceJune 14, 2022 | finance.yahoo.comCalithera Biosciences Announces 1-for-20 Reverse Stock SplitJune 13, 2022 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.comJune 5, 2022 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Earns Hold Rating from Analysts at StockNews.comMay 27, 2022 | finance.yahoo.comAfter a record-breaking decade, biotech is discovering what hard times feel likeMay 17, 2022 | finance.yahoo.comCalithera to Present at the H.C. Wainwright Global Investment ConferenceMay 11, 2022 | seekingalpha.comCalithera Biosciences stock slips after PT cut at LadenburgMay 11, 2022 | seekingalpha.comCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | finance.yahoo.comCalithera Biosciences Reports First Quarter 2022 Financial Results and Recent HighlightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALA CUSIPN/A CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees92Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today6/30/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$50.00 High Stock Price Forecast$80.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+1,932.5%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($28.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-115.09 million Net MarginsN/A Pretax Margin-1,113.11% Return on Equity-141.76% Return on Assets-76.15% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio4.16 Sales & Book Value Annual Sales$9.75 million Price / Sales1.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book1.13Miscellaneous Outstanding Shares4,862,000Free Float4,541,000Market Cap$11.96 million OptionableOptionable Beta1.64 Calithera Biosciences Frequently Asked Questions Should I buy or sell Calithera Biosciences stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Calithera Biosciences stock. View analyst ratings for Calithera Biosciences or view top-rated stocks. What is Calithera Biosciences' stock price forecast for 2022? 4 equities research analysts have issued 12 month target prices for Calithera Biosciences' shares. Their CALA stock forecasts range from $30.00 to $80.00. On average, they anticipate Calithera Biosciences' stock price to reach $50.00 in the next twelve months. This suggests a possible upside of 1,932.5% from the stock's current price. View analysts' price targets for Calithera Biosciences or view top-rated stocks among Wall Street analysts. How has Calithera Biosciences' stock price performed in 2022? Calithera Biosciences' stock was trading at $13.30 at the beginning of 2022. Since then, CALA shares have decreased by 81.5% and is now trading at $2.46. View the best growth stocks for 2022 here. When is Calithera Biosciences' next earnings date? Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Calithera Biosciences. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) issued its earnings results on Tuesday, May, 10th. The biotechnology company reported ($3.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.40) by $0.20. During the same quarter in the prior year, the business earned ($5.60) earnings per share. View Calithera Biosciences' earnings history. When did Calithera Biosciences' stock split? How did Calithera Biosciences' stock split work? Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of Calithera Biosciences stock prior to the reverse split would have 5 shares after the split. Who are Calithera Biosciences' key executives? Calithera Biosciences' management team includes the following people: Dr. Susan M. Molineaux Ph.D., Founder, CEO, Pres & Director (Age 68, Pay $923.21k)Ms. Stephanie Wong, CFO & Sec. (Age 48, Pay $616.4k)Dr. Eric B. Sjogren, Sr. VP of Drug Discovery (Age 65, Pay $579.13k)Dr. Christopher J. Molineaux Ph.D., Sr. VP of Devel. (Age 69)Mr. Frank Parlati Ph.D., Sr. VP of Research (Age 53)Dr. Emil T. Kuriakose M.D., Chief Medical Officer (Age 42)Dr. Susan B. Demo Ph.D., Sr. VP of R&D OperationsDr. Allison Dillon Ph.D., Sr. VP of Commercial & Portfolio Strategy Who are some of Calithera Biosciences' key competitors? Some companies that are related to Calithera Biosciences include Corvus Pharmaceuticals (CRVS), Vaccinex (VCNX), RedHill Biopharma (RDHL), SELLAS Life Sciences Group (SLS), Athenex (ATNX), Societal CDMO (SCTL), Novan (NOVN), Processa Pharmaceuticals (PCSA), Neoleukin Therapeutics (NLTX), Galecto (GLTO), Hepion Pharmaceuticals (HEPA), Gain Therapeutics (GANX), Chemomab Therapeutics (CMMB), Purple Biotech (PPBT) and Longboard Pharmaceuticals (LBPH). View all of CALA's competitors. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." How do I buy shares of Calithera Biosciences? Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $2.46. How much money does Calithera Biosciences make? Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $11.96 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115.09 million in net income (profit) each year or ($28.80) on an earnings per share basis. How many employees does Calithera Biosciences have? Calithera Biosciences employs 92 workers across the globe. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for Calithera Biosciences is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at [email protected]. This page (NASDAQ:CALA) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
